MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Suletud

SektorTervishoid

1.16 5.45

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.1

Max

1.16

Põhinäitajad
By Trading Economics
Sissetulek	1.8M -32M
Müük	-166K 1.7M
Kasumimarginaal	-1,852.384
Töötajad	181
EBITDA	7.9M -29M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+321.82% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	3. märts 2026

Turustatistika
By TradingEconomics
Turukapital	12M 137M
Eelmine avamishind	-4.29
Eelmine sulgemishind	1.16

Uudiste sentiment

By Acuity

67%

33%

325 / 360 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

21. jaan 2026, 23:49 UTC

Suurimad hinnamuutused turgudel

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21. jaan 2026, 21:12 UTC

Suurimad hinnamuutused turgudel

Automaker Stocks Rise After Trump Calls Off European Tariffs

21. jaan 2026, 21:00 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21. jaan 2026, 20:29 UTC

Suurimad hinnamuutused turgudel

Chip Makers Gain After Trump Calls Off European Tariffs

21. jaan 2026, 20:04 UTC

Suurimad hinnamuutused turgudel

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21. jaan 2026, 23:48 UTC

Market Talk

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21. jaan 2026, 23:34 UTC

Market Talk

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21. jaan 2026, 22:39 UTC

Tulu

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21. jaan 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

21. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21. jaan 2026, 21:35 UTC

Omandamised, ülevõtmised, äriostud

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21. jaan 2026, 21:19 UTC

Tulu

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21. jaan 2026, 20:45 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Borse Group to Acquire Allfunds for $6.19B

21. jaan 2026, 20:36 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21. jaan 2026, 20:31 UTC

Market Talk

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21. jaan 2026, 20:27 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21. jaan 2026, 20:27 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21. jaan 2026, 20:27 UTC

Market Talk

Was It a 'TACO' Event? -- Market Talk

21. jaan 2026, 20:26 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21. jaan 2026, 20:23 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21. jaan 2026, 20:21 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21. jaan 2026, 20:19 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse Group Agrees to Buy Allfunds

21. jaan 2026, 20:08 UTC

Tulu

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21. jaan 2026, 20:03 UTC

Market Talk

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21. jaan 2026, 19:51 UTC

Market Talk

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21. jaan 2026, 19:43 UTC

Market Talk

U.S. Ethanol Production Expected to Slip -- Market Talk

21. jaan 2026, 19:31 UTC

Market Talk

Gold Settles at Fresh All-Time High -- Market Talk

21. jaan 2026, 19:24 UTC

Tulu

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21. jaan 2026, 19:10 UTC

Market Talk

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21. jaan 2026, 18:57 UTC

Market Talk

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

321.82% tõus

12 kuu keskmine prognoos

Keskmine 4.64 USD 321.82%

Kõrge 8 USD

Madal 2 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

325 / 360 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.